title: Weekly epirubicin in advanced breast cancer.
abstract: Twenty-nine advanced breast cancer patients, considered unable to tolerate conventional cytotoxic chemotherapy, were treated with a weekly schedule of epirubicin (15 mg/m2 i.v.). All patients were fully evaluable. A remission of 34.5% was observed (2 CR; 8 PR), with a median duration of response of 9 months (range, 3-24 months). Side effects were mild, and on the whole the toxicity was negligible. This regimen showed a favorable therapeutic ratio in our series and seems active and well tolerated even in elderly and/or poor performance status patients.
authors.affiliation: Istituto di Radiologia, Università di Siena, Italia.
authors.forename: E
authors.initials: E
authors.lastname: Tucci
authors.forename: R
authors.initials: R
authors.lastname: Algeri
authors.forename: A
authors.initials: A
authors.lastname: Guarnieri
authors.forename: F
authors.initials: F
authors.lastname: Pepi
authors.forename: L
authors.initials: L
authors.lastname: Sapio
authors.forename: G
authors.initials: G
authors.lastname: Bastreghi
authors.forename: L
authors.initials: L
authors.lastname: Pirtoli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged
chemical_list: D015251:Epirubicin